[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status
Background: The efficacy of erlotinib is controversial in patients with unknown EGFR
mutational status. The aim of this study was to identify the clinicopathological factors that are …
mutational status. The aim of this study was to identify the clinicopathological factors that are …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
Y Ikezawa, H Asahina, S Oizumi, M Watanabe… - Cancer chemotherapy …, 2017 - Springer
Purpose A high proportion of patients with wild-type EGFR non-small cell lung cancer
(NSCLC) receive third-line therapy and beyond, with no prospective randomized trials …
(NSCLC) receive third-line therapy and beyond, with no prospective randomized trials …
[HTML][HTML] Comparison of effectiveness of Gefitinib, Erlotinib, and Afatinib in advanced non-small cell lung cancer patients with EGFR mutation positive in Indonesian …
N Sutandyo, A Hanafi, M Jayusman - Chinese journal of lung …, 2019 - ncbi.nlm.nih.gov
Methods A retrospective cohort study of 88 NSCLC patients with EGFR mutation positive
treated with gefitinib (n= 59), erlotinib (n= 22), and afatinib (n= 7) was performed in national …
treated with gefitinib (n= 59), erlotinib (n= 22), and afatinib (n= 7) was performed in national …
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
R Garcia-Campelo, O Arrieta, B Massuti… - Lung Cancer, 2020 - Elsevier
Objectives Progression-free survival (PFS) and response rate to epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung …
receptor (EGFR) tyrosine kinase inhibitors (TKIs) varies in patients with non-small-cell lung …
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer
L Timmers, CCLM Boons, J Moes-Ten Hove… - Journal of cancer …, 2015 - Springer
Purpose Erlotinib is an orally administered tyrosine kinase inhibitor used for treatment of non-
small cell lung cancer. Understanding actual use of medication is essential for optimizing …
small cell lung cancer. Understanding actual use of medication is essential for optimizing …
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy …
FA Shepherd, J Pereira, TE Ciuleanu… - Journal of Clinical …, 2004 - ascopubs.org
7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
Impact of smoking history on the efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutations
S Igawa, J Sasaki, S Otani, M Ishihara, A Takakura… - Oncology, 2015 - karger.com
Background: Gefitinib treatment has come to be recognized as the standard therapy for
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor …
Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis
O Abdel-Rahman, M Fouad - Expert Review of Anticancer Therapy, 2015 - Taylor & Francis
We performed a meta-analysis of diarrhea and stomatitis associated with erlotinib use in
patients with advanced non-small cell lung cancer. Eligible studies included randomized …
patients with advanced non-small cell lung cancer. Eligible studies included randomized …